Bristol Myers Squibb has priced a €5 billion senior unsecured notes offering, set to close on November 10, 2025. The offering comprises five tranches of notes with varying maturity dates and interest rates, fully guaranteed by Bristol-Myers Squibb Company. On November 3, 2025, the company initiated a tender offer to purchase outstanding notes for cash, aiming to utilize the offering's net proceeds, along with $3 billion in cash, for the tender offer and general corporate purposes. Citigroup Global Markets Limited, Barclays Bank PLC, BNP PARIBAS, J.P. Morgan Securities plc, and Société Générale are acting as joint lead managers and book-running managers. The offering is backed by a shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC). Investors can access the prospectus and preliminary prospectus supplement for free on EDGAR, the SEC's website. However, this press release does not constitute an offer to sell or purchase securities, and no offers will be made in jurisdictions where unlawful. Bristol Myers Squibb cautions that this release contains forward-looking statements, which are subject to risks and uncertainties, including market conditions, interest rate fluctuations, and credit and foreign exchange risks. These statements are based on current expectations and projections, and the company undertakes no obligation to update them. Bristol Myers Squibb's mission is to develop innovative medicines to improve patients' lives, driven by bold scientific pursuits.
